Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1987 Apr;63(738):245–247. doi: 10.1136/pgmj.63.738.245

Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo.

H Sinzinger 1, J O'Grady 1, P Fitscha 1
PMCID: PMC2428153  PMID: 3684830

Abstract

The effects of infusions of prostaglandin E1 (PGE1) on platelet deposition at atherosclerotic sites in vivo in man have been examined. Thirteen patients with atherosclerotic vascular disease received intravenous PGE1 25 mg/kg/min for 6 hours daily for 5 days. Prostaglandin E1 had no effect on platelet uptake at atherosclerotic sites but prolonged platelet half-life significantly (P less than 0.001).

Full text

PDF
245

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carlson L. A., Olsson A. G. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet. 1976 Oct 9;2(7989):810–810. doi: 10.1016/s0140-6736(76)90653-x. [DOI] [PubMed] [Google Scholar]
  2. Feldman S. M., Alpert J., Dick L. S., Brief D. K., Goldenkranz R., Brener B. J., Parsonnet V. Clinical observations with intravenous prostaglandin E1 in peripheral vascular disease. J Med Soc N J. 1982 Dec;79(13):985–987. [PubMed] [Google Scholar]
  3. Lewis P. J., Dollery C. T. Clinical pharmacology and potential of prostacyclin. Br Med Bull. 1983 Jul;39(3):281–284. doi: 10.1093/oxfordjournals.bmb.a071834. [DOI] [PubMed] [Google Scholar]
  4. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  5. Pardy B. J., Lewis J. D., Eastcott H. H. Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease. Surgery. 1980 Dec;88(6):826–832. [PubMed] [Google Scholar]
  6. Rhodes R. S., Heard S. E. Detrimental effect of high-dose prostaglandin E1 in the treatment of ischemic ulcers. Surgery. 1983 Jun;93(6):839–842. [PubMed] [Google Scholar]
  7. Sakaguchi S., Kusaba A., Mishima Y., Kamiya K., Nishimura A., Furukawa K., Shionoya S., Kawashima M., Katsumura T., Sakuma A. A multi-clinical double blind study with PGE, (alpha-cyclodextrin clathrate) in patients with ischemic ulcer of the extremities. Vasa. 1978;7(3):263–266. [PubMed] [Google Scholar]
  8. Schuler J. J., Flanigan D. P., Holcroft J. W., Ursprung J. J., Mohrland J. S., Pyke J. Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial. J Vasc Surg. 1984 Jan;1(1):160–170. doi: 10.1067/mva.1984.avs0010160. [DOI] [PubMed] [Google Scholar]
  9. Sethi G. K., Scott S. M., Takaro T. Effect of intra-arterial infusion of PGE1 in patients with severe ischemia of lower extremity. J Cardiovasc Surg (Torino) 1980 Mar-Apr;21(2):185–192. [PubMed] [Google Scholar]
  10. Sinzinger H., Fitscha P. Epoprostenol and platelet deposition in atherosclerosis. Lancet. 1984 Apr 21;1(8382):905–906. doi: 10.1016/s0140-6736(84)91363-1. [DOI] [PubMed] [Google Scholar]
  11. Sinzinger H., Kolbe H., Strobl-Jäger E., Höfer R. A simple and safe technique for sterile autologous platelet labelling using "Monovette" vials. Eur J Nucl Med. 1984;9(7):320–322. doi: 10.1007/BF00276462. [DOI] [PubMed] [Google Scholar]
  12. Sinzinger H., O'Grady J., Cromwell M., Hofer R. Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic grafts. Lancet. 1983 Jun 4;1(8336):1275–1276. doi: 10.1016/s0140-6736(83)92721-6. [DOI] [PubMed] [Google Scholar]
  13. Sinzinger H., Reiter S. The intrainfusion platelet rebound during and following PGE1-infusion is faster and more intensive than that with PGI2. Prostaglandins Leukot Med. 1984 Mar;13(3):281–288. doi: 10.1016/0262-1746(84)90041-6. [DOI] [PubMed] [Google Scholar]
  14. Szczeklik A., Nizankowski R., Skawinski S., Szczeklik J., Gluszko P., Gryglewski R. J. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet. 1979 May 26;1(8126):1111–1114. doi: 10.1016/s0140-6736(79)91792-6. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES